Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
Public ClinicalTrials.gov record NCT06297603. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Multicenter, Double-Blind Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly Compared With Placebo in Adult Participants With Type 2 Diabetes, Moderate or Severe Renal Impairment With Inadequate Glycemic Control on Basal Insulin With or Without Metformin and/or SGLT2 Inhibitor
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and renal impairment, with inadequate glycemic control on basal insulin alone or a combination of basal insulin with or without metformin and/or sodium-glucose cotransporter-2 (SGLT2) inhibitor. The study will last about 14 months and may include up to 22 visits.
Study identification
- NCT ID
- NCT06297603
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 320 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 15, 2024 (Actual)
- Primary completion
- Oct 2026 (Estimated)
- Completion
- Nov 2026 (Estimated)
- Last update posted
- Jul 20, 2026
2024 – 2026
United States locations
- U.S. sites
- 28
- U.S. states
- 16
- U.S. cities
- 27
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Nephrology Consultants | Huntsville | Alabama | 35805 | — |
| Clinical Research Institute of Arizona (CRI) - Sun City West | Sun City West | Arizona | 85375 | — |
| Kidney & Hypertension Center - Apple Valley | Apple Valley | California | 92307 | — |
| Hope Clinical Research, Inc. | Canoga Park | California | 91303 | — |
| Neighborhood Healthcare Institute of Health | Escondido | California | 92025 | — |
| EndoTrials Center for Clinical Research | La Mesa | California | 91942 | — |
| UCLA South Bay Endocrinology | Torrance | California | 90505 | — |
| Northeast Research Institute (NERI) | Fleming Island | Florida | 32003 | — |
| Encore Medical Research - Weston | Weston | Florida | 33331 | — |
| Orita Clinical Research | Decatur | Georgia | 30034 | — |
| CARE Institute | Idaho Falls | Idaho | 83404 | — |
| Cotton O'Neil Diabetes & Endocrinology | Topeka | Kansas | 66606 | — |
| Billings Clinic | Billings | Montana | 59101 | — |
| Excel Clinical Research, LLC | Las Vegas | Nevada | 89109 | — |
| Albany Medical College, Division of Community Endocrinology | Albany | New York | 12203 | — |
| NYC Research INC | Long Island City | New York | 11106 | — |
| Research Foundation of SUNY - University of Buffalo | Williamsville | New York | 14221 | — |
| University of North Carolina Medical Center | Chapel Hill | North Carolina | 27514 | — |
| Central States Research | Tulsa | Oklahoma | 74136 | — |
| Preferred Primary Care Physicians, Preferred Clinical Research-St. Clair | Pittsburgh | Pennsylvania | 15243 | — |
| AM Diabetes & Endocrinology Center | Bartlett | Tennessee | 38133 | — |
| Velocity Clinical Research, Dallas | Dallas | Texas | 75230 | — |
| Prime Revival Research Institute, LLC | Flower Mound | Texas | 75098 | — |
| Juno Research | Houston | Texas | 77040 | — |
| PlanIt Research, PLLC | Houston | Texas | 77079 | — |
| Southern Endocrinology Associates | Mesquite | Texas | 75149 | — |
| Texas Valley Clinical Research | Weslaco | Texas | 78596 | — |
| Diabetes & Endocrine Treatment Specialists | Sandy City | Utah | 84093 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 48 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06297603, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 20, 2026 · Synced Oct 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06297603 live on ClinicalTrials.gov.